Abstract 116P
Background
Colorectal cancer (CRC) ranks as the second leading cause of mortality, following lung cancer, among cancer-related fatalities in High Income Asia Pacific (HIAP) nations. Despite this, there remains a lack of consistent and comparable data on the burden of CRC in these regions.
Methods
Utilizing tools from the Global Burden of Disease study, we examined CRC's prevalence, incidence, mortality, and disability-adjusted life years (DALYs) by age groups, sex, and years across four HIAP countries from 1990-2019. Moreover, we employed a regression framework model to project CRC-related deaths until 2040.
Results
The aggregate number of prevalent CRC cases surged from 450,169 (95%UI: 433,127-466,354) in 1990 to 1,178,847 (1,026,274-1,347,590) in 2019. During the same period, the death toll increased from 34,338 (32,598-35,179) to 76,929 (64,820-83,603). When considering the annual percentage change (APC), DALYs exhibited a 65% increase from 1990 to 2019. Notably, the age-standardized incidence rate (ASIR) demonstrated a 15% rise in APC, with the most pronounced increases occurring in South Korea (119%), Brunei Darussalam (21%), and Japan (13%). Conversely, Singapore exhibited a 7% decline in ASIR during the same timeframe. In terms of age-standardized mortality rate (ASMR), South Korea reported the highest APC (17%), while Singapore and Japan witnessed declines of 40% and 15%, respectively. The most significant APC in DALYs was noted in Brunei Darussalam (178%), trailed by South Korea (176%), Japan (89%), and Singapore (50%). In 2019, the age group of 85-89 experienced the highest CRC-related deaths, whereas the 75-79 age group exhibited the highest incidence. Meanwhile, the 70-74 age group showed the highest DALYs. Over the past three decades, males carried a greater burden compared to females. By 2040, a projected increase of 73,633 (52,895-102,526) CRC-related deaths is anticipated.
Conclusions
In 2019, CRC contributed to 13.88% of all cancer-related casualties in HIAP nations. The burden of CRC varied persistently among these countries. Nonetheless, it is evident that there is an urgent requirement for the implementation of more effective strategies to mitigate the burden posed by CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract